Treatment areas
Oncology
Medical conditions
Cancer,
Lung cancer
Drug classes
Ras GTPase inhibitor
General Information
Adagrasib is a cancer medicine that treats non-small cell lung cancer (NSCLC) with an abnormal KRAS G12C gene.
Indications for Genetic Testing
Adagrasib is metabolized by the CYP3A4 enzyme. Genetic variations in the CYP3A4 gene and concomitant medication can affect drug clearance and risk of side effects.
Additional Information
Avoid concomitant use of adagrasib with other products with a known potential to prolong the QTc interval. Monitor ECG and electrolytes in patients at risk and in patients taking medications known to prolong the QT interval. Common side effects include hepatotoxicity and gastrointestinal adverse reactions. Monitor liver laboratory tests prior to the start of adagrasib and monthly for 3 months after and as clinically indicated. Monitor patients for diarrhea, nausea and vomiting and provide supportive care as needed. Withhold, reduce the dose or permanently discontinue based on severity.